Additional Study Information: This study is for patients with incurable cancers such as, metastatic non-small cell lung cancer, melanoma, renal cell carcinoma, triple negative breast cancer, colorectal cancer, head and neck cancer, castrate resistant prostate cancer and bladder cancer. The purpose of this study is find out whether an investigational (experimental) drug called CPI-444 can be used, either on its own, or in combination with another investigational drug called atezolizumab (also known as MPDL3280A) on patients and the specific type of cancer they have. We want to find out the best dose of CPI-444, both on its own and in combination with atezolizumab and what effects, good and/or bad, either CPI-444 on its own or in combination with atezolizumab has on patients with incurable cancers.